On June 27, 2008 China Biopharma Inc (CBPC)-OTCBB hit 400 number of trades and made it to 0.0028 from 0.0011, The number of trades were at 257 to begin with, and Now the number of trades is 757 and should run again. The high on Friday was 0.0028. We never saw one do this. We always saw them at the beginning of 400 not at 757 and down. Think of this as starting at 757 number of trades or # of transactions. We will see what happens. The bid for Monday June 30, 2008 is 0.0014 The Ask is 0.0018. This one will be fun.

Company Information:

China Biopharma Inc. (CBI), formerly Techedge, Inc. (Techedge) is a provider of bio-pharmaceutical products with primary focus on the development and sale of human vaccines. The Company develops its products in China and distributes these products in China. The Company has established its distribution and development platform in China and as a result of its acquisition of its interest in its subsidiary, Hainan CITIC Bio-pharmaceutical Development Co., Ltd. (HCBD) and, as a result of its joint venture with Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd. (Zhejiang Tianyan). The Company’s products primarily consist of vaccines for preventing and treating various diseases and illnesses in humans.

Company Contact:

Address 31 Airpark Road
Princeton, NJ 08540
Telephone (609) 651-8588
Fax (609) 228-4301
http://www.chinabiopharma.net/

Press Release

China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products

2008-03-26

China Biopharma Reaches Agreement with a Regional Pharma
to Launch New Pharmaceutical Products

HANGZHOU, China, March 26 /PRNewswire-FirstCall/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC - News) announced today that it has reached agreement with Beijing Keyuan Xinhai Pharmaceutical Company to launch newly approved pharmaceutical products made by leading international pharmaceutical companies. According to the agreement, China Biopharma will distribute pharmaceutical products made by international companies including human vaccines in China using its sales network and distribution logistics.

In the last few months, the company has made effort to extend its market scope and establish new partnership in addition to the original JV partner, Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd. Due to certain local tax regulations the Company\'s sales of the products of its original JV partner could not be fully recognized. In order to effectively conduct its business operation and change from its passive marketing approach in China, the Company has shifted its market strategy to working more closely with new pharmaceutical products from global leading pharmaceutical companies in addition to local products. \"We are very excited about the agreement we have reached with Beijing Keyuan Xinhai Pharmaceutical Company,\" said Mr. Qiumeng Wang, the Company\'s COO. \"It will significantly improve our current operation situation.\" Beijing Keyuan Xinhai Pharmaceutical Company is one of the largest imported pharmaceutical product providers in China.

About China Biopharma, Inc.

China Biopharma Inc. is a biopharmaceutical company based in China. Through its operating subsidiaries, the company develops and distributes biopharmaceutical and pharmaceutical products throughout the world\'s most populated country, China. Products include human vaccines and other pharmaceutical drugs. Leveraging its local presents and the relationship with local Chinese bio-pharmaceutical companies and international biopharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as new world markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.net.

Safe Harbor Statement
Some of the statements here discuss future events and developments, including the Company\'s future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These \"forward-looking\" statements can generally be identified by words such as \"expect,\" \"anticipate,\" \"believe,\" \"estimate,\" \"intend,\" \"plan,\" and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company\'s operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company\'s new and uncertain business model, uncertainty regarding acceptance of the Company\'s products and services and the Company\'s limited operating history.

CONTACT:

China Biopharma, Inc.
Tel: +1 (609) 651-8588 This e-mail address is being protected from spam bots, you need JavaScript enabled to view it http://www.chinabiopharma.net

Chart:

good observation, my charts show this stock just dropped below the bollinger bands which already have a large standard deviation showing high volatility and the buy signal, i'd probably wait until the ADX shows more support for a new trend, and the moving averages to crossover. also this stock is undervalued, if my funds wern't tied up i would go in, nice insight figment.

Thank you.

Opus. Explain in more detail of what you're talking about please. Use charts too =) . You're covering a topic i need more knowledge on.

okay, unfortunately the y-axis is stretched so it\'s difficult to see the SMA and bollinger bands, but if you use the interactive charts on www.bigcharts.com it adjusts it more accurately, i drew in some annotations as well..




It\'s always difficult to tell with penny stock though...never know what\'s in store..

Volumes up over 10,000,000 ask 0.0014 Nice buy in point

what kind of a run can we expect?

I didn't buy in yet probably waitng for a 0.000 surge

Should run soon

about 90,000,000 in volume seems to be key